Adamis Pharmaceuticals resubmits NDA for Zimhi for the treatment of opioid overdose..
Adamis Pharmaceuticals Corporation announced the resubmission of the Company’s New Drug Application (“NDA”) to the FDA for its Zimhi (naloxone HCI Injection, USP) 5mg/0.5mL product candidate for the… read more.